The Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)1 found that, in patients with schizophrenia whose medication was changed for clinical reasons, first (FGA)- and second (SGA)-generation antipsychotics were associated with comparable 1-year outcomes on measures of clinical improvement, adverse effects, quality of life, and costs of care. We have several concerns about the study: